<?xml version='1.0' encoding='utf-8'?>
<document id="25985298"><sentence text="In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents."><entity charOffset="24-35" id="DDI-PubMed.25985298.s1.e0" text="Fluconazole" /><entity charOffset="40-52" id="DDI-PubMed.25985298.s1.e1" text="Dipyridamole" /><pair ddi="false" e1="DDI-PubMed.25985298.s1.e0" e2="DDI-PubMed.25985298.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25985298.s1.e0" e2="DDI-PubMed.25985298.s1.e1" /></sentence><sentence text="Weakly basic drugs typically exhibit pH-dependent solubility in the physiological pH range, displaying supersaturation or precipitation along the gastrointestinal tract" /><sentence text=" Additionally, their oral bioavailabilities may be affected by coadministration of acid-reducing agents that elevate gastric pH" /><sentence text=" The purpose of this study was to assess the feasibility of a multicompartmental in vitro dissolution apparatus, Gastrointestinal Simulator (GIS), in predicting in vivo dissolution of certain oral medications" /><sentence text=" In vitro dissolution studies of fluconazole, a BCS class I, and dipyridamole, a BCS class II weak bases (class IIb), were performed in the GIS as well as United States Pharmacopeia (USP) apparatus II and compared with the results of clinical drug-drug interaction (DDI) studies"><entity charOffset="33-44" id="DDI-PubMed.25985298.s5.e0" text="fluconazole" /><entity charOffset="65-77" id="DDI-PubMed.25985298.s5.e1" text="dipyridamole" /><pair ddi="false" e1="DDI-PubMed.25985298.s5.e0" e2="DDI-PubMed.25985298.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25985298.s5.e0" e2="DDI-PubMed.25985298.s5.e1" /></sentence><sentence text=" In both USP apparatus II and GIS, fluconazole completely dissolved within 60 min regardless of pH, reflecting no DDI between fluconazole and acid-reducing agents in a clinical study"><entity charOffset="35-46" id="DDI-PubMed.25985298.s6.e0" text="fluconazole" /><entity charOffset="126-137" id="DDI-PubMed.25985298.s6.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.25985298.s6.e0" e2="DDI-PubMed.25985298.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25985298.s6.e0" e2="DDI-PubMed.25985298.s6.e1" /></sentence><sentence text=" On the other hand, seven-fold and 15-fold higher concentrations of dipyridamole than saturation solubility were observed in the intestinal compartments in GIS with gastric pH 2"><entity charOffset="68-80" id="DDI-PubMed.25985298.s7.e0" text="dipyridamole" /></sentence><sentence text="0" /><sentence text=" Precipitation of dipyridamole was also observed in the GIS, and the percentage of dipyridamole in solution was 45"><entity charOffset="18-30" id="DDI-PubMed.25985298.s9.e0" text="dipyridamole" /><entity charOffset="83-95" id="DDI-PubMed.25985298.s9.e1" text="dipyridamole" /><pair ddi="false" e1="DDI-PubMed.25985298.s9.e0" e2="DDI-PubMed.25985298.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25985298.s9.e0" e2="DDI-PubMed.25985298.s9.e1" /></sentence><sentence text="2 ± 7" /><sentence text="0%" /><sentence text=" In GIS with gastric pH 6" /><sentence text="0, mimicking the coadministration of acid-reducing agents, the concentration of dipyridamole was equal to its saturation solubility, and the percentage of drug in solution was 9"><entity charOffset="80-92" id="DDI-PubMed.25985298.s13.e0" text="dipyridamole" /></sentence><sentence text="3 ± 2" /><sentence text="7%" /><sentence text=" These results are consistent with the clinical DDI study of dipyridamole with famotidine, which significantly reduced the Cmax and area under the curve"><entity charOffset="61-73" id="DDI-PubMed.25985298.s16.e0" text="dipyridamole" /><entity charOffset="79-89" id="DDI-PubMed.25985298.s16.e1" text="famotidine" /><pair ddi="false" e1="DDI-PubMed.25985298.s16.e0" e2="DDI-PubMed.25985298.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25985298.s16.e0" e2="DDI-PubMed.25985298.s16.e1" /></sentence><sentence text=" An In situ mouse infusion study combined with GIS revealed that high concentration of dipyridamole in the GIS enhanced oral drug absorption, which confirmed the supersaturation of dipyridamole"><entity charOffset="87-99" id="DDI-PubMed.25985298.s17.e0" text="dipyridamole" /><entity charOffset="181-193" id="DDI-PubMed.25985298.s17.e1" text="dipyridamole" /><pair ddi="false" e1="DDI-PubMed.25985298.s17.e0" e2="DDI-PubMed.25985298.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25985298.s17.e0" e2="DDI-PubMed.25985298.s17.e1" /></sentence><sentence text=" In conclusion, GIS was shown to be a useful apparatus to predict in vivo dissolution for BCS class IIb drugs" /><sentence text=" " /></document>